ERAS
Erasca Inc
NASDAQ · Biotechnology
$12.29
+0.41 (+3.45%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 897.62M | 918.48M | 827.43M |
| Net Income | -100,463,137 | -95,918,574 | -115,001,691 |
| EPS | — | — | — |
| Profit Margin | -11.2% | -10.4% | -13.9% |
| Rev Growth | +16.3% | +1.8% | +8.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 487.48M | 423.83M | 373.12M |
| Total Equity | 1.97B | 1.68B | 1.92B |
| D/E Ratio | 0.25 | 0.25 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -104,291,949 | -115,509,109 | -110,721,792 |
| Free Cash Flow | -130,963,293 | -137,514,931 | -125,568,165 |